Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03735446 · ClinicalTrials.gov registry record · Phase 1
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03735446 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 2 participants.
The verdict
NCT03735446, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This research study is studying a targeted therapy combined with chemotherapy as a possible treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). The drugs involved in this study are: * Prexasertib (LY2606368) * Mitoxantrone * Etoposide * Cytarabine
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Mitoxantrone
- DRUG Prexasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-01-18 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03735446
The ClinicalTrials.gov registry entry for NCT03735446 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Etoposide is the first listed.
NCT03735446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03735446 about?
NCT03735446 is a clinical study titled "Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial". This research study is studying a targeted therapy combined with chemotherapy as a possible treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). The drugs involved in this study are: * Prexasertib (LY2606368) * Mitoxantrone * Etoposide * Cytarabine
What is the current status of trial NCT03735446?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-01-18. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03735446?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Mitoxantrone (DRUG), Prexasertib (DRUG).
Who is sponsoring clinical trial NCT03735446?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.